REG - Renalytix PLC - Update Regarding Forward Guidance

RenalytixAnnouncement

24/09/2025 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250924:nRSX6757Aa&default-theme=true

RNS Number : 6757A  Renalytix PLC  24 September 2025

 

Renalytix plc

("Renalytix" or the "Company")

 

Update Regarding Forward Guidance

 

LONDON and NEW YORK, 24 September 2025 - Renalytix plc (LSE: RENX) a precision
medicine company with kidneyintelX.dkd, the only FDA-approved and Medicare
reimbursed prognostic test to support early-stage risk assessment in chronic
kidney disease, provides a further comment regarding revenue guidance
following the Company's announcement dated 23 September 2025.

 

The Company would like to clarify that the forward revenue guidance provided
does not include full consideration of the implications of its recently
announced collaboration with Tempus AI
(https://www.londonstockexchange.com/news-article/RENX/tempus-ai-inc-collaboration-agreement/17230023)
, Inc. ("Tempus"). As it is too early to predict revenue contributions from
this new relationship with Tempus, the Company expects to provide shareholders
with updates in due course.

 

For further information, please contact:

 

 Renalytix Plc                                                           www.renalytix.com (http://www.renalytix.com)

 James McCullough, CEO                                                   Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)     Tel: 0203 470 0470

 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Sole Bookrunner and Joint Broker)                       Tel: 020 3179 5300

 Mike Seabrook / Nick Lovering / Aimee McCusker

 Walbrook PR Limited                 Tel: 020 7933 8780 or renalytix@walbrookpr.com

                                   (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings

                                     Mob: 07980 541 893 / 07407 804 654

 

The person responsible for making this Announcement on behalf of the Company
is

James McCullogh, Chief Executive Officer.

 

 

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of
kidney disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now
offered commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical
validation, kidneyintelX.dkd is the only FDA-approved and Medicare
reimbursed prognostic tool capable of understanding a patient's risk with
kidney disease early where treatment has maximal effect. kidneyintelX.dkd is
now being deployed across large physician group practices and health systems
in select regions of the United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by
Medicare, the largest insurance payer in the United States, at $950 per
reportable result. kidneyintelX.dkd is also recommended for use in the
international chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix. For information about the
kidneyintelX,dkd test, visit kidneyintelx.com (http://kidneyintelx.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDZGZLZDLGKZM